We use cookies and similar tools to give you the best website experience. By using our site, you accept our Websites Privacy Policy.
Perlmutter Cancer Center Highlights 2019–2020
Trial provides new options for bacillus Calmette-Guérin–unresponsive non-muscle invasive type.
Read Story
Research, Translational Medicine
Four promising projects aim to discover which patients will experience benefits or toxicity.
Perlmutter Cancer Center Highlights, Perlmutter Cancer Center Highlights 2019–2020
These phase 2 trials provide new options for treating glioblastomas and meningiomas.
Research, Patient Care
Studies show decreases in postoperative morbidity, pain, and recovery time compared with thoracotomy.
New programs are changing how individuals are screened for genetic risk for cancer.
Dozens of trials explore a wide variety of drug strategies and tumor types.
Clinicians, researchers, and patients work together to increase 5-year survival rate to 50 percent.
Download Print Version (PDF)
We can help you find a doctor. Call 646-929-7800 or browse our specialists.
